Titleβ-Adrenergic receptor blockade blunts postexercise skeletal muscle mitochondrial protein synthesis rates in humans.
Publication TypeJournal Article
Year of Publication2011
AuthorsRobinson, MM, Bell, C, Peelor, FF, Miller, BF
JournalAm J Physiol Regul Integr Comp Physiol
Volume301
Issue2
PaginationR327-34
Date Published2011 Aug
ISSN1522-1490
KeywordsAdrenergic beta-Agonists, Adrenergic beta-Antagonists, Adult, Cross-Over Studies, Gene Expression Regulation, Humans, Isoproterenol, Male, Muscle Proteins, Muscle, Skeletal, Propranolol, Young Adult
Abstract

β-Adrenergic receptor (AR) signaling is a regulator of skeletal muscle protein synthesis and mitochondrial biogenesis in mice. We hypothesized that β-AR blockade blunts postexercise skeletal muscle mitochondrial protein synthesis rates in adult humans. Six healthy men (mean ± SD: 26 ± 6 yr old, 39.9 ± 4.9 ml·kg(-1)·min(-1) peak O(2) uptake, 26.7 ± 2.0 kg/m(2) body mass index) performed 1 h of stationary cycle ergometer exercise (60% peak O(2) uptake) during 1) β-AR blockade (intravenous propranolol) and 2) administration of saline (control). Skeletal muscle mitochondrial, myofibrillar, and sarcoplasmic protein synthesis rates were assessed using [(2)H(5)]phenylalanine incorporation into skeletal muscle proteins after exercise. The mRNA content of signals for mitochondrial biogenesis was determined using real-time PCR. β-AR blockade decreased mitochondrial (from 0.217 ± 0.076 to 0.135 ± 0.031%/h, P < 0.05), but not myofibrillar or sarcoplasmic, protein synthesis rates. Peroxisome proliferator-activated receptor-γ coactivator-1α mRNA was increased ∼2.5-fold (P < 0.05) at 5 h compared with 1 h postexercise but was not influenced by β-AR blockade. We conclude that decreased β-AR signaling during cycling can blunt the postexercise increase in mitochondrial protein synthesis rates without affecting mRNA content.

DOI10.1152/ajpregu.00160.2011
Alternate JournalAm. J. Physiol. Regul. Integr. Comp. Physiol.
PubMed ID21613574
PubMed Central IDPMC3154708
Grant List1-K01-AG-031829-01A1 / AG / NIA NIH HHS / United States